AZLI + Placebo
Phase 3Terminated 2 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization
Conditions
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Trial Timeline
Nov 28, 2017 → Sep 23, 2021
NCT ID
NCT03219164About AZLI + Placebo
AZLI + Placebo is a phase 3 stage product being developed by Gilead Sciences for Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization. The current trial status is terminated. This product is registered under clinical trial identifier NCT03219164. Target conditions include Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis.
What happened to similar drugs?
1 of 4 similar drugs in Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization were approved
Approved (1) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03219164 | Phase 3 | Terminated |
| NCT01313624 | Phase 3 | Completed |
| NCT01314716 | Phase 3 | Completed |
| NCT01059565 | Phase 3 | Completed |
Competing Products
8 competing products in Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0292 | AstraZeneca | Phase 2 | 42 |
| tobramycin + tobramycin | Novartis | Phase 3 | 40 |
| Tobramycin inhalation powder | Novartis | Phase 3 | 40 |
| TIS or TIP | Novartis | Approved | 35 |
| Ciprofloxacin (Cipro, BAYQ3939) | Bayer | Phase 1 | 26 |
| Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | Insmed | Phase 3 | 37 |
| TOBI® PODHALER® + TOBI® + Bethkis® + Cayston® | Viatris | Pre-clinical | 23 |
| IC43 + Placebo | Valneva SE | Phase 2/3 | 32 |